355 related articles for article (PubMed ID: 25091027)
1. Effect of peginterferon alfa-2b and ribavirin on hepatocellular carcinoma prevention in older patients with chronic hepatitis C.
Honda T; Ishigami M; Masuda H; Ishizu Y; Kuzuya T; Hayashi K; Itoh A; Hirooka Y; Nakano I; Ishikawa T; Urano F; Yoshioka K; Toyoda H; Kumada T; Katano Y; Goto H
J Gastroenterol Hepatol; 2015 Feb; 30(2):321-8. PubMed ID: 25091027
[TBL] [Abstract][Full Text] [Related]
2. Sustained HCV clearance by interferon-based therapy reduces hepatocellular carcinoma in hepatitis B and C dually-infected patients.
Hung CH; Lu SN; Wang JH; Hu TH; Chen CH; Huang CM; Lee CM
Antivir Ther; 2011; 16(7):959-68. PubMed ID: 22024511
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: a prospective, multicenter study.
Ogawa E; Furusyo N; Kajiwara E; Takahashi K; Nomura H; Maruyama T; Tanabe Y; Satoh T; Nakamuta M; Kotoh K; Azuma K; Dohmen K; Shimoda S; Hayashi J;
J Hepatol; 2013 Mar; 58(3):495-501. PubMed ID: 23099187
[TBL] [Abstract][Full Text] [Related]
4. The tertiary prevention of hepatocellular carcinoma in chronic hepatitis C patients.
Huang JF; Yeh ML; Yu ML; Dai CY; Huang CF; Huang CI; Tsai PC; Lin PC; Chen YL; Chang WT; Hou NJ; Lin ZY; Chen SC; Chuang WL
J Gastroenterol Hepatol; 2015 Dec; 30(12):1768-74. PubMed ID: 26094738
[TBL] [Abstract][Full Text] [Related]
5. The efficacy and safety of pegylated interferon plus ribavirin combination therapy in chronic hepatitis c patients with hepatocellular carcinoma post curative therapies - a multicenter prospective trial.
Huang JF; Yu ML; Huang CF; Chiu CF; Dai CY; Huang CI; Yeh ML; Yang JF; Hsieh MY; Hou NJ; Lin ZY; Chen SC; Wang LY; Chuang WL
J Hepatol; 2011 Feb; 54(2):219-26. PubMed ID: 21056500
[TBL] [Abstract][Full Text] [Related]
6. Treatment Response and Long-Term Outcome of Peginterferon α and Ribavirin Therapy in Korean Patients with Chronic Hepatitis C.
Jung CH; Um SH; Kim TH; Yim SY; Suh SJ; Yim HJ; Seo YS; Choi HS; Chun HJ
Gut Liver; 2016 Sep; 10(5):808-17. PubMed ID: 27114417
[TBL] [Abstract][Full Text] [Related]
7. Risk factors of hepatocellular carcinoma development in non-cirrhotic patients with sustained virologic response for chronic hepatitis C virus infection.
Toyoda H; Kumada T; Tada T; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Kitabatake S; Ito T
J Gastroenterol Hepatol; 2015 Jul; 30(7):1183-9. PubMed ID: 25678094
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of pegylated interferon alfa-2b and ribavirin combination therapy versus pegylated interferon monotherapy in hemodialysis patients: a comparison of 2 sequentially treated cohorts.
Tseng PL; Chen TC; Chien YS; Hung CH; Yen YH; Chang KC; Tsai MC; Lin MT; Lee CT; Shen CH; Hu TH
Am J Kidney Dis; 2013 Oct; 62(4):789-95. PubMed ID: 23746377
[TBL] [Abstract][Full Text] [Related]
9. Maintenance therapy with peginterferon alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C.
Bruix J; Poynard T; Colombo M; Schiff E; Burak K; Heathcote EJ; Berg T; Poo JL; Mello CB; Guenther R; Niederau C; Terg R; Bedossa P; Boparai N; Griffel LH; Burroughs M; Brass CA; Albrecht JK;
Gastroenterology; 2011 Jun; 140(7):1990-9. PubMed ID: 21419770
[TBL] [Abstract][Full Text] [Related]
10. High post-treatment absolute monocyte count predicted hepatocellular carcinoma risk in HCV patients who failed peginterferon/ribavirin therapy.
Chen TM; Lin CC; Huang PT; Wen CF
Tumour Biol; 2016 Jun; 37(6):7129-37. PubMed ID: 26662957
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of pegylated interferon and ribavirin combination therapy for patients with hepatitis C virus infection after curative resection or ablation for hepatocellular carcinoma--A retrospective multicenter study.
Harada N; Hiramatsu N; Oze T; Tatsumi T; Hayashi N; Takehara T
J Med Virol; 2015 Jul; 87(7):1199-206. PubMed ID: 25772024
[TBL] [Abstract][Full Text] [Related]
12. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
[TBL] [Abstract][Full Text] [Related]
13. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C.
Lok AS; Everhart JE; Wright EC; Di Bisceglie AM; Kim HY; Sterling RK; Everson GT; Lindsay KL; Lee WM; Bonkovsky HL; Dienstag JL; Ghany MG; Morishima C; Morgan TR;
Gastroenterology; 2011 Mar; 140(3):840-9; quiz e12. PubMed ID: 21129375
[TBL] [Abstract][Full Text] [Related]
14. Peginterferon alfa-2a plus ribavirin is more effective than peginterferon alfa-2b plus ribavirin for treating chronic hepatitis C virus infection.
Ascione A; De Luca M; Tartaglione MT; Lampasi F; Di Costanzo GG; Lanza AG; Picciotto FP; Marino-Marsilia G; Fontanella L; Leandro G
Gastroenterology; 2010 Jan; 138(1):116-22. PubMed ID: 19852964
[TBL] [Abstract][Full Text] [Related]
15. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis.
Cardoso AC; Moucari R; Figueiredo-Mendes C; Ripault MP; Giuily N; Castelnau C; Boyer N; Asselah T; Martinot-Peignoux M; Maylin S; Carvalho-Filho RJ; Valla D; Bedossa P; Marcellin P
J Hepatol; 2010 May; 52(5):652-7. PubMed ID: 20346533
[TBL] [Abstract][Full Text] [Related]
16. Baseline gamma-glutamyl transferase levels strongly correlate with hepatocellular carcinoma development in non-cirrhotic patients with successful hepatitis C virus eradication.
Huang CF; Yeh ML; Tsai PC; Hsieh MH; Yang HL; Hsieh MY; Yang JF; Lin ZY; Chen SC; Wang LY; Dai CY; Huang JF; Chuang WL; Yu ML
J Hepatol; 2014 Jul; 61(1):67-74. PubMed ID: 24613362
[TBL] [Abstract][Full Text] [Related]
17. Predicting early and sustained virological responses in prior nonresponders to pegylated interferon alpha-2b plus ribavirin retreated with peginterferon alpha-2a plus ribavirin and the benefit-risk ratio of retreatment.
Marcellin P; Craxi A; Brandao-Mello CE; Di Bisceglie AM; Andreone P; Freilich B; Rajender Reddy K; Olveira Martín A; Teuber G; Messinger D; Hooper G; Wat C; Tatsch F; Jensen DM
J Clin Gastroenterol; 2013 Oct; 47(9):786-93. PubMed ID: 23442834
[TBL] [Abstract][Full Text] [Related]
18. Risk factors for hepatocellular carcinoma in hepatitis C patients with normal alanine aminotransferase treated with pegylated interferon and ribavirin.
Harada N; Hiramatsu N; Oze T; Morishita N; Yamada R; Hikita H; Miyazaki M; Yakushijin T; Miyagi T; Yoshida Y; Tatsumi T; Kanto T; Kasahara A; Oshita M; Mita E; Hagiwara H; Inui Y; Katayama K; Tamura S; Yoshihara H; Imai Y; Inoue A; Hayashi N; Takehara T
J Viral Hepat; 2014 May; 21(5):357-65. PubMed ID: 24716638
[TBL] [Abstract][Full Text] [Related]
19. A comparison of peginterferon α-2a and α-2b for treatment-naive patients with chronic hepatitis C virus: A meta-analysis of randomized trials.
Zhao S; Liu E; Chen P; Cheng D; Lu S; Yu Q; Wang Y; Wei K; Yang P
Clin Ther; 2010 Aug; 32(9):1565-77. PubMed ID: 20974315
[TBL] [Abstract][Full Text] [Related]
20. Boceprevir with peginterferon alfa-2a-ribavirin is effective for previously treated chronic hepatitis C genotype 1 infection.
Flamm SL; Lawitz E; Jacobson I; Bourlière M; Hezode C; Vierling JM; Bacon BR; Niederau C; Sherman M; Goteti V; Sings HL; Barnard RO; Howe JA; Pedicone LD; Burroughs MH; Brass CA; Albrecht JK; Poordad F
Clin Gastroenterol Hepatol; 2013 Jan; 11(1):81-87.e4; quiz e5. PubMed ID: 23064222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
